{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:14:05Z","timestamp":1793812445009,"version":"4.6.1"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T00:00:00Z","timestamp":1588896000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.critrevonc.2020.102969","type":"journal-article","created":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T12:50:42Z","timestamp":1589201442000},"page":"102969","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["A user\u2019s guide to lorlatinib"],"prefix":"10.1016","volume":"151","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5308-615X","authenticated-orcid":false,"given":"Misako","family":"Nagasaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yubin","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1968-0459","authenticated-orcid":false,"given":"Ammar","family":"Sukari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geetika","family":"Kukreja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai-Hong Ignatius","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2020.102969_bib0005","doi-asserted-by":"crossref","first-page":"5093","DOI":"10.2147\/OTT.S165511","article-title":"Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date","volume":"11","author":"Akamine","year":"2018","journal-title":"Onco. Targets Ther."},{"key":"10.1016\/j.critrevonc.2020.102969_bib0010","unstructured":"https:\/\/www.uptodate.com\/contents\/lorlatinib-drug-information?source=history_widget (Last Accessed 7 August 2019)."},{"key":"10.1016\/j.critrevonc.2020.102969_bib0015","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210868s000lbl.pdf (Accessed 4 January 2020)."},{"key":"10.1016\/j.critrevonc.2020.102969_bib0020","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/212725s000lbl.pdf (Accessed 4 January 2020)."},{"key":"10.1016\/j.critrevonc.2020.102969_bib0025","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1215530","article-title":"Acquired resistance to crizotinib from a mutation in CD74-ROS1","volume":"368","author":"Awad","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.critrevonc.2020.102969_bib0030","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1634\/theoncologist.2018-0380","article-title":"Clinical management of adverse events associated with lorlatinib","volume":"24","author":"Bauer","year":"2019","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.critrevonc.2020.102969_bib0035","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11523-020-00702-4","article-title":"Brain penetration of lorlatinib: cumulative incidences of CNS and Non-CNS progression with lorlatinib in patients with previously treated ALK-positive non-small-cell lung cancer","volume":"15","author":"Bauer","year":"2020","journal-title":"Target. Oncol."},{"issue":"6835","key":"10.1016\/j.critrevonc.2020.102969_bib0040","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/35077225","article-title":"Oncogenic kinase signaling","volume":"411","author":"Blume-Jensen","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2020.102969_bib0045","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus crizotinib in ALK-Positive non-small-Cell lung Cancer","volume":"379","author":"Camidge","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2020.102969_bib0050","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.9011","article-title":"Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1 fusion-positive non-small cell lung cancer (TRIDENT-1 study)","volume":"37","author":"Cho","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.102969_bib0055","doi-asserted-by":"crossref","first-page":"15761","DOI":"10.1038\/ncomms15761","article-title":"Synthesis and preliminary PET imaging of 11C and 18F isotopologues of the ROS1\/ALK inhibitor lorlatinib","volume":"8","author":"Collier","year":"2017","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.critrevonc.2020.102969_bib0060","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12943-018-0776-2","article-title":"Role and targeting of anaplastic lymphoma kinase in cancer","volume":"17","author":"Della Corte","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2020.102969_bib0065","article-title":"Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three pjase 1-2 trials","author":"Drilon","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2020.102969_bib0070","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-16-0596","article-title":"Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer","volume":"6","author":"Gainor","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2020.102969_bib0075","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1158\/1078-0432.CCR-15-3101","article-title":"EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis","volume":"22","author":"Gainor","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2020.102969_bib0080","doi-asserted-by":"crossref","DOI":"10.1200\/PO.17.00063","article-title":"Patterns of metastatic spread and mechanisms of resistance to crizotinib in ROS1-positive non-small cell lung cancer","author":"Gainor","year":"2017","journal-title":"J Clin Oncol Precision Oncol"},{"key":"10.1016\/j.critrevonc.2020.102969_bib0085","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(17)30565-2","article-title":"Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial","volume":"390","author":"Hida","year":"2017","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.critrevonc.2020.102969_bib0090","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/j.jtho.2019.08.003","article-title":"Monitoring therapeutic response and resistance: analysis of circulating tumor DNA in patients with ALK+ lung Cancer","volume":"14","author":"Horn","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2020.102969_bib0095","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1021\/jm401805h","article-title":"Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib","volume":"57","author":"Huang","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.critrevonc.2020.102969_bib0100","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/PPO.0000000000000142","article-title":"Anaplastic lymphoma kinase as a therapeutic target in non-small cell lung cancer","volume":"21","author":"Iams","year":"2015","journal-title":"Cancer J."},{"issue":"11","key":"10.1016\/j.critrevonc.2020.102969_bib0105","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.1021\/jm500261q","volume":"57","author":"Johnson","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.critrevonc.2020.102969_bib0110","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1158\/1078-0432.CCR-14-1385","article-title":"Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer","volume":"21","author":"Katayama","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.critrevonc.2020.102969_bib0115","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1200\/JCO.2017.76.2294","article-title":"Impact of EML4-ALK variant on resistance mechanisms and clinical outcomes in ALK-positive lung cancer","volume":"36","author":"Lin","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2020.102969_bib0120","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jtho.2019.10.014","article-title":"Efficacy of platinum\/pemetrexed combination chemotherapy in ALK-Positive NSCLC refractory to second-generation ALK inhibitors","volume":"15","author":"Lin","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2020.102969_bib0125","series-title":"Non-Small Cell Lung Cancer. (Version2.2020-December 23, 2019)","author":"National Comprehensive Cancer Network","year":"2020"},{"key":"10.1016\/j.critrevonc.2020.102969_bib0130","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.clpt.2006.09.003","article-title":"Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance","volume":"80","author":"Neuvonen","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.critrevonc.2020.102969_bib0135","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ebiom.2019.01.019","article-title":"Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance","volume":"41","author":"Okada","year":"2019","journal-title":"EBioMedicine."},{"key":"10.1016\/j.critrevonc.2020.102969_bib0140","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-Positive non-small-Cell lung Cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2020.102969_bib0145","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.lungcan.2013.07.025","article-title":"Genetic alterations defining NSCLC subtypes and their therapeutic implications","volume":"82","author":"Pikor","year":"2013","journal-title":"Lung Cancer"},{"issue":"11","key":"10.1016\/j.critrevonc.2020.102969_bib0150","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/s41571-018-0081-4","article-title":"Making the first move in EGFR-driven or ALK-driven NSCLC: first generation or next-generation TKI?","volume":"15","author":"Recondo","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2020.102969_bib0155","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1158\/1078-0432.CCR-19-1104","article-title":"Diverse resistance mechanisms to the third-generation ALK inhibitor lorlatinib in ALK-Rearranged lung Cancer","volume":"26","author":"Recondo","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2020.102969_bib0160","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1056\/NEJMoa1406766","article-title":"Crizotinib in ROS1-rearranged non-small-cell lung cancer","volume":"371","author":"Shaw","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2020.102969_bib0165","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1508887","article-title":"Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F","volume":"374","author":"Shaw","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.critrevonc.2020.102969_bib0170","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S1470-2045(17)30680-0","article-title":"Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 study","volume":"18","author":"Shaw","year":"2017","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2020.102969_bib0175","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S1470-2045(19)30655-2","article-title":"Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial","volume":"20","author":"Shaw","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2020.102969_bib0180","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.critrevonc.2020.102969_bib0185","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S1470-2045(18)30649-1","article-title":"Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study","volume":"19","author":"Solomon","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2020.102969_bib0190","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0140-6736(17)30123-X","article-title":"First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study","volume":"389","author":"Soria","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2020.102969_bib0195","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.jtho.2018.02.022","article-title":"Phase 1\/2 study of the safety and tolerability of nivolumab plus crizotinib for the first-line treatment of anaplastic lymphoma kinase translocation-positive advanced non-small cell lung cancer (CheckMate 370)","volume":"13","author":"Spigel","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2020.102969_bib0200","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s40265-018-1041-0","article-title":"Lorlatinib: first global approval","volume":"79","author":"Syed","year":"2019","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.critrevonc.2020.102969_bib0205","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1245\/s10434-009-0808-7","article-title":"Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene","volume":"17","author":"Takahashi","year":"2010","journal-title":"Ann. Surg. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2020.102969_bib0210","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2213-2600(19)30252-8","article-title":"Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial","volume":"8","author":"Yang","year":"2020","journal-title":"Lancet Respir. Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2020.102969_bib0215","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1158\/2159-8290.CD-17-1256","article-title":"Sequential ALK inhibitors can select for lorlatinib-resistant compound ALK mutations in ALK-positive lung cancer","volume":"8","author":"Yoda","year":"2018","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.critrevonc.2020.102969_bib0220","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ccell.2015.05.010","article-title":"PF-06463922, an ALK\/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models","volume":"28","author":"Zou","year":"2015","journal-title":"Cancer Cell"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842820301074?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842820301074?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:33:05Z","timestamp":1760902385000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842820301074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":44,"alternative-id":["S1040842820301074"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2020.102969","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A user\u2019s guide to lorlatinib","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2020.102969","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102969"}}